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Abstract
Objective To assess the effects of a patient oriented decision aid for
prioritising treatment goals in diabetes compared with usual care on
patient empowerment and treatment decisions.
Design Pragmatic randomised controlled trial.
Setting 18 general practices in the north of the Netherlands.
Participants 344 patients with type 2 diabetes aged ≤65 years at the
time of diagnosis and managed in primary care between April 2011 and
August 2012: 225 were allocated to the intervention group and 119 to
the usual care group.
Intervention The intervention comprised a decision aid for people with
diabetes, with individually tailored risk information and treatment options
for multiple risk factors. The aid was intended to empower patients to
prioritise between clinical domains and to support treatment decisions.
It was offered to participants before a regular diabetes check-up and to
their healthcare provider during the consultation. Four different formats
of the decision aid were included for additional explorative analyses.
Main outcome measures The primary outcome was the effects on
patient empowerment for setting and achieving goals. The secondary
outcomes were changes in the prescribing of drugs to regulate glucose,
blood pressure, lipids, and albuminuria. Data were collected through
structured questionnaires and automated data extraction from electronic
health records during six months before and after the intervention.
Results Of all intervention participants, 103 (46%) reported to have
received the basic elements of the intervention. For the primary outcome
analysis, 199 intervention and 107 control patients with sufficient baseline
and follow-up data could be included. The mean empowerment score
increased 0.1 on a 5 point scale in the overall intervention group, which
was not significantly different from that of the control group (mean
difference after adjusting for baseline 0.039, 95% confidence interval
−0.056 to 0.134). Lipid regulating drug treatment was intensified in 25%
of intervention and 12% of control participants with increased cholesterol
levels, which did not reach significance when the intervention was
compared with the usual care group (odds ratio 2.54, 95% confidence
interval 0.89 to 7.23). Prespecified explorative analyses showed that
this effect was significant for the printed version of the decision aid in
comparison to usual care (3.90, 1.29 to 11.80). No relevant or significant
changes were seen for other treatments.
ConclusionWe found no evidence that the patient oriented treatment
decision aid improves patient empowerment by an important amount.
The aid was not used to its full extent in a substantial number of
participants.
Trial registration Dutch trial register NTR1942.
Introduction
Adequate treatment targeting multiple risk factors can prevent
or slow the progression of complications in people with
diabetes.1 2Despite improvements observed in several processes
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of diabetes care in the past decade, the control of risk factors
remains suboptimal.3-5 Two modifiable factors have been
identified, which are likely to contribute to these suboptimal
results.6 7 Firstly, clinicians are sometimes hesitant to intensify
treatment in people with increased levels of risk factors.8 In
addition, patients may show poor adherence to drugs,9 which is
not always acknowledged by their clinician.10 11
Models of chronic care emphasise the need for a collaborative
approach between patient and healthcare providers to achieve
effective disease management.12 13 They must work together to
identify problems, set priorities, establish goals, and make
treatment plans.14 15 A proactive role by patients may also result
in a more timely adjustment of drugs by their doctors.16 17
Although the concept of a collaborative approach is widely
acknowledged, it is not yet an integral part of daily practice.18
Decision aids or support systems can encourage patient-provider
discussions about disease management by presenting available
treatment options and expected outcomes for each patient.19
Most aids, however, focus on one specific treatment choice,
whereas people with diabetes are often confronted with multiple
clinical domains (glucose, blood pressure, lipids) for which
treatment is indicated. The newest generation decision aids
prioritise between domains to support treatment decisions, but
their effect when used jointly by patient and healthcare provider
has not yet been evaluated.20 21
We present the results of a pragmatic randomised controlled
trial of a newly developed patient oriented decision aid for
prioritising treatment goals in diabetes. Our primary aim was
to assess the effect of the decision aid compared with usual care
on patient empowerment for setting and achieving goals. We
expected that more empowerment would translate as patients
getting more involved in the process of goal setting and decision
making to achieve those goals and subsequently in intensified
drug treatment in patients not achieving goals. We anticipated
that the intervention could also lead to potentially negative
effects on other patient outcomes. Our secondary aim was to
explore the impact of different presentation formats and
modifying effects of patient characteristics and to learn more
about how the aid was used in daily practice.
Methods
Study setting and recruitment of practices
A total of 18 general practices were recruited in the north of the
Netherlands. In this region, a diabetes disease management
programme was implemented in 2007. As part of this
programme, each practice receives a performance report yearly.
All general practices use electronic medical record systems
supporting structured care protocols and were eligible for
inclusion.Most practices have a nurse practitioner or specialised
assistant for diabetes care who carries out the quarterly diabetes
checks and is trained to conduct physical examinations, risk
assessments, patient education, and counselling. Changes in
drug treatment can be proposed by such staff but have to be
approved by the general practitioner.
To ensure a comparable level of communication skills we
offered all the practices a training course in motivational
interviewing before the study started. If they had already been
on such a course, the practices were offered €250 (£199; $324)
as incentive to participate. In addition, all participants received
a two hour training session in risk communication, including
role play with simulation patients and an instruction video with
simulated consultations showing “good” and “bad” examples
of applying four basic principles of risk communication—that
is, to use natural frequencies, positive and negative phrasing,
and explicit uncertainty, and to be open and refrain from
imposing options.
Patient population and recruitment
We included people with type 2 diabetes who were managed in
primary care. We excluded patients who had had a myocardial
infarction in the preceding year; experienced a stroke; had heart
failure, angina pectoris, or a terminal illness; and were aged
more than 65 years at the time their diabetes was diagnosed.
For these patients the calculated risks using the intervention
tool were not considered sufficiently evidence based. There was
no restriction on duration of diabetes or age at time of inclusion.
After we had identified potentially eligible patients from the
electronic medical record system, we presented a random
selection of at least 40 patients per practice to the healthcare
provider, who was asked to confirm the eligibility criteria and
exclude patients with dementia, cognitive deficits, blindness,
or an inability to read Dutch. We chose this procedure since
these exclusion criteria could not be reliably identified from the
medical records. We used random selections because in large
practices we did not want to burden healthcare providers with
the verification of all potentially eligible patients. Between April
2011 and August 2012, these patients received an information
package distributed by their healthcare provider and containing
an invitation letter, information about the project, and an
informed consent form. Patients were offered €10 for time spent
on completing the study questionnaires.
Intervention
We developed a decision aid for people with diabetes, which
presents individually tailored information on risks and treatment
options for multiple risk factors. Specific risk factors included
HbA1c, systolic blood pressure, low density lipoprotein
cholesterol, and smoking. The rationale, goals, and a detailed
description of the decision aid have been presented previously.22
In short, the aid focuses on shared goal setting and decision
making, particularly with respect to the drug treatment of risk
factors.We followed a stepwise development process, including
active involvement and testing with patients and providers.22
The decision aid shows several graphs using individually tailored
information. Risks calculated with the United Kingdom
Prospective Diabetes Study risk score were explained in positive
and negative terms and expressing uncertainty. For example,
“Out of 100 patients with the same age, gender, and disease
characteristics as you, 16 are expected to get a heart attack
within the next five years and 84 will not get a heart attack. At
this moment, we cannot say to which group you will belong.”
Graphs are then presented showing potential risk reductions
with possible treatment options and questions posed to the
patient (see supplementary figure 1 and22).
Key features, identified as being relevant for productive
patient-provider interaction, included a personal status report
including test results and current drug treatment; the presentation
of tailored information on achievable treatment goals and
possible treatment options for specific risk factors; a
combination of graphs and text using natural frequencies for
outcome probabilities; the presentation of pros and cons of all
treatment options; and asking patients to think about treatment
options.22 The aid retrieves clinical information directly from
the electronic medical record. It should be used by patients
before a regular quarterly check-up and discussed jointly with
their healthcare provider during the consultation to help them
prioritise on treatment that will maximise relevant outcomes.
The software is integrated in the electronic medical record
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system,making use of all available information but also allowing
for additional data entry or corrections. The software is
complemented with a set of treatment cards that can be used
during consultation, summarising the positive and side effects
of the various treatment options, including doing nothing (see
supplementary fig 2).
A short instruction protocol was provided on how to use the
software and treatment cards before and during a consultation.22
To summarise, before the consultation the healthcare provider
needed to start the software, check the content, and print the
information. The patients were asked to come to the practice
15 minutes in advance to go through the information, either in
print or on the computer. During the consultation, healthcare
providers were expected to support patients to think about
treatment goals and options, making use of the computer screen
or printed version of the information. When appropriate,
healthcare providers could present and compare specific
treatment options using the treatment cards. The consultation
ideally was to be concluded with clear action points. At the end
of the consultation, the printed version was to be distributed to
all intervention patients. When the regular scheduled time was
too short, a further consultation could be planned to finalise the
shared decision making.
Patients in the control group received care as usual—that is,
their regular quarterly check-up, including any education,
information, or additional consultations as deemed necessary
by their healthcare provider.
Design and treatment allocation
A primary analysis was conducted to assess the effect of the
decision aid compared with usual care. To explore the impact
of different formats, we included four versions for presenting
the information to patients in a 2×2 factorial design: a computer
screen or printed version, presented either as a short version,
showing treatment effects on myocardial infarction risk only,
or as an extended version, including effects on additional
outcomes (stroke, amputation, blindness, renal failure).
We randomly allocated participating practices to the computer
screen or printed version. A stratified computer generated
allocation sequence was used, defining four strata by practice
size (<2500 patients or >2500 patients) and organisation type
(single general practitioner or several general practitioners).
Within each practice, consenting patients were randomised to
receive the short version presenting only myocardial infarction
risk outcomes, the extended version presenting additional
outcomes, or to the control group. We used a predefined
computer algorithm with a blockwise scheme to conceal the
allocation process from the healthcare provider.
Outcome measures
Our primary outcome was the empowerment of patients for
setting and achieving goals, as assessed with the diabetes
empowerment scale – subscale for setting and achieving diabetes
goals (DES-III).23 This instrument can be downloaded from the
website of theMichigan Diabetes Research and Training Center
(www.med.umich.edu/mdrtc/profs/survey.html#des).
Furthermore, we assessed changes in treatment. This included
measures assessing intensification of drug treatment for patients
with increased HbA1c levels, systolic blood pressure, or low
density lipoprotein cholesterol levels, and treatment with renin
angiotensin system inhibiting agents. In addition, we explored
the effects of the decision aid on secondary patient outcomes.
These were:
• other diabetes self efficacy aspects, as measured with the
diabetes empowerment subscales for managing the
psychosocial aspects of diabetes (DES-I), and assessing
dissatisfaction and readiness to change (DES-II)
• beliefs about medicines, as measured with the beliefs about
medication questionnaire—subscales necessity, concerns,
general overuse, and general harm24
• satisfaction with diabetes care, as measured with the
patients’ evaluation of quality of diabetes care
questionnaire25
• negative emotions, as measured with the problem areas in
diabetes questionnaire26




Effects of the decision aid may depend on characteristics of the
patients that affect their involvement, understanding, and
patient-provider communication about disease management.
Therefore, we tested several characteristics as possible
modifying factors: age, low educational level (representing not
more than primary school or lower vocational education), short
duration of diabetes (<3 years), number of uncontrolled risk
factors (0-4 scale for HbA1c, systolic blood pressure, low
density lipoprotein cholesterol, smoking), a high number of
related drugs at baseline (>3 glucose, blood pressure, or lipid
regulating drugs), or polypharmacy (>4 drugs for chronic
illnesses) at baseline.
Data collection
We used structured questionnaires to collected patient survey
data, which were mailed to the patients in the month before and
three to four months after the scheduled quarterly check-up. In
the post-intervention questionnaire, intervention patients rated
how easy or difficult they perceived the decision aid on a 5 point
Likert scale, which we re-coded into a binary difficulty score
(yes=difficult, no=neutral or easy). We collected data on patient
characteristics, smoking status, and drugs in the six months
before and after the intervention period from the GIANTT
(Groningen initiative to analyse type 2 diabetes treatment)
database. This database includes longitudinal data collected
from primary care medical records using validated automated
extraction procedures.28 Diabetes duration was based on
information provided by the healthcare provider. We calculated
the United Kingdom Prospective Diabetes Study risk score and
the number of uncontrolled risk factors at baseline using the
last values for HbA1c, blood pressure, cholesterol, and smoking
status in the year before the consultation. Since no valid
information on ethnicity was available, and more than 90% of
the population in the study region is white, we used “white”
ethnicity for calculation of the risk score.29
Process evaluation
In the post-intervention questionnaire, intervention patients
were asked whether they received the aid before their
consultation, discussed the cardiovascular risk during the
consultation with their healthcare provider, and discussed how
such risks could be reduced. For the extended version, patients
answered one additional question: whether they also discussed
other diabetes related risks. This information was used for a per
protocol analysis where we included only patients who answered
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yes to all questions. In addition, healthcare providers were asked
to complete a short checklist after each consultation with an
intervention patient about their perception of how the decision
aid was used before and during the consultation.
Sample size
The sample size was preliminary estimated at 150 patients per
study arm to achieve a power of 80% at a 5% significance level
for detecting a 0.2 absolute difference in the diabetes
empowerment score, which was the primary outcome, between
the overall intervention and control group.22 Since there is no
published minimum level of relevant change in the diabetes
empowerment subscale,30 and the standard deviation in the
empowerment score at baseline was smaller than assumed for
this preliminary estimation, we conducted a retrospective power
calculation after all patients were included and baseline data
were collected. With a total number of 199 patients in the
intervention group and 107 in the control group for the primary
outcome analysis and an observed standard deviation of 0.46
for the empowerment score, we achieved an 80% power at 5%
significance level to detect a difference in the empowerment
score of 0.15.
Statistical analysis
We used descriptive statistics to summarise personal, clinical,
and other patient outcomes and calculated standardised
differences to check for imbalance between the intervention and
usual care group.31 The effects of the intervention were tested
in an intention to treat analysis comparing the patient groups
not adjusted for clustering. We assumed that the effect of the
decision aid on patient empowerment was mainly influenced
by patient and not by practice characteristics. To check this, we
conducted a multilevel analysis to estimate whether the practice
level had an impact on the primary outcome. The proportion of
variance that was accounted for at this level was calculated as
the intraclass correlation coefficient. This coefficient was 0.059
for the primary patient outcome, indicating that there was not
much variance due to practice related factors (see supplementary
table 1). We tested effects using linear and logistic regression
models, adjusting for baseline values of the outcome of interest.
We present regression coefficients as the effect size measure
for the linear models, indicating the mean difference between
the intervention and control group after adjusting for baseline.
For the logistic regression models, we present odds ratios with
95% confidence intervals. Imbalance, which was defined as a
standardised difference of more than 0.1, was observed in some
of the variables, indicating that randomisation was not fully
successful. Because of this imbalance, we conducted additional
analyses adjusting for unbalanced baseline patient
characteristics. We used multiple imputation by chained
equations to impute missing baseline values for risk factors and
educational level. Results were combined across 20 imputed
datasets using Rubin’s rules.32 We evaluated interactions of the
intervention with each of the effect modifiers. Finally,
explorative analyses were conducted to compare the effects for
each of the intervention formats with the usual care group
separately, and to compare the computer screen with the printed
version, as well as the short with the extended version. Data
were analysed using Stata version 12.
Results
The 18 included general practices had an average patient
population of 4380. Eleven practices had one nurse practitioner,
nurse, or specialised assistant for diabetes care, six had two or
three nurse practitioners or specialised assistants, and one had
no such staff. Together these were the 25 healthcare providers
who conducted the quarterly diabetes check-ups and therefore
worked with the decision aid and received the training on risk
communication using the aid. Our stratified randomisation
scheme based on practice size and number of general
practitioners resulted in an equal distribution of the printed and
computer screen version among practices with one or more than
one healthcare provider working with the decision aid.
Of the people with diabetes and identified as potentially eligible
in the electronic medical records of the 18 practices, 1769 were
assessed for exclusion criteria (figure⇓). Of the resulting 665
eligible patients, 370 (56%) consented to participate. For 344,
a practice consultation was anticipated during the study
intervention period, and these patients were randomised to the
intervention (n=225) or usual care group (n=119). The
intervention patients were comparable to usual care patients for
age, sex, and educational level (table 1⇓). Although being treated
less often with insulin and more often with sulphonylurea
derivatives and other oral glucose regulating drugs, more
intervention than usual care patients had a well controlled
HbA1c level at baseline. On the other hand, more usual care
patients had a well controlled blood pressure level at baseline.
Overall, however, the groups were comparable for the number
of uncontrolled risk factors and the number of drugs used at
baseline. Only 15% of the intervention patients and 18% of the
usual care patients showed adequate control for all risk factors.
Intervention patients had slightly lower empowerment scores,
higher beliefs about the necessity of their treatment, and a lower
general health status (table 1).
Use of the decision aid
The decision aid was accessed at the consultation date for 198
of the 225 intervention patients; for eight no session was planned
within the study period, for seven the aid was accessed after the
planned consultation date, and for 12 the session failed to be
logged because of technical problems. In total, 103 patients
reported to have received all basic elements of the intervention.
These patients were significantly younger (60.0 v 63.6 years),
had higher HbA1c levels (6.9% v 6.7%), andmore uncontrolled
risk factors (on average 1.5 v 1.3) at baseline than patients who
reported not receiving the full intervention. They were similar
for sex, educational level, drug treatment, and baseline responses
to the questionnaires (see supplementary table 2).
Effect on patient reported outcomes
Baseline patient empowerment scores were available for 212
intervention and 110 usual care patients (table 1), whereas
outcomes scores were available for 207 and 108 patients,
respectively (table 2⇓). The average empowerment score for
setting and achieving goals increased by 0.1 on a 5 point Likert
scale among the patients in the intervention group, which was
not significantly different from the usual care group (effect size
0.039, 95% confidence interval −0.056 to 0.134, table 2). No
significant effects were observed for any of the other patient
reported outcomes, including satisfaction with diabetes care,
negative emotions, and general health status.
Adjustment on unbalanced patient characteristics did not change
the effect of the intervention on empowerment for setting and
achieving goals (effect size 0.045, 95% confidence interval
−0.055 to 0.139, see supplementary table 3a). The results for
the per protocol analysis were similar (0.058, −0.055 to 0.172,
see supplementary table 3b). Age, educational level, duration
of diabetes, number of uncontrolled risk factors, and number of
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drugs used at baseline did not modify the effect of the
intervention on empowerment (see supplementary table 4).
Effect on treatment
In patients not reaching the low density lipoprotein cholesterol
target of 2.5 mmol/L, lipid regulating treatment was intensified
in 25% of the intervention patients compared with 12% of the
usual care patients. This effect was not significant (odds ratio
2.54, 95% confidence interval 0.89 to 7.23, table 3⇓). No
differences were seen for intensification of drug treatment in
patients not reaching HbA1c or blood pressure targets or in the
prescribing of renin angiotensin system inhibiting agents.
Results were similar on adjustment of unbalanced patient
characteristics and for the per protocol analysis (see
supplementary tables 3a and b). The effect of the intervention
was not significantly modified by age, level of education,
duration of diabetes, number of uncontrolled risk factors, and
number of drugs used at baseline (see supplementary table 4).
Different presentation formats
None of the presentation formats of the decision aid showed a
significant effect on patient empowerment (see supplementary
table 5). More intensified lipid regulating treatment was seen
for patients who received the printed version compared with
usual care (odds ratio 3.90, 95% confidence interval 1.29 to
11.80), and comparing the computer screen with the printed
version (0.34, 0.12 to 0.98, see supplementary table 5).
Differences in intensified blood pressure and glucose regulating
treatment, favouring the printed and the extended version,
respectively, were only observed when these formats were
compared with each other but not when compared with usual
care (see supplementary table 5).
Evaluation by patients
For all four presentation formats, more than three quarters of
the patients reported receiving the decision aid before the
consultation (table 4⇓). Discussion of risks and possible risk
reductions was lowest in the group receiving the extended screen
version. These patients also had the lowest number of
uncontrolled risk factors and risk score (table 4). Only 10
patients perceived the information as difficult, including seven
who had received the extended version of the aid. Most patients
who received the computer screen version before the
consultation also received the printed version during or after
the consultation as planned. Almost 30% reported that they
preferred the printed version over the screen version, whereas
most of the others did not have a preference (table 4).
Quantitative evaluation by healthcare
providers
For 185 of the 217 intervention consultations (85%), the
healthcare providers completed the checklists after the
consultations about the decision aid and the decision making
process. Two general practices, both randomised to the printed
version, did not complete these checklists. According to the
healthcare providers, almost all patients received the aid before
the consultation. This included 26 patients (15 computer screen
group, 11 printed version group) who reported not having seen
the aid. Patients in the computer screen group were more often
assisted by practice staff than patients in the printed version
group (table 4). The providers reported that they discussed
possible risk reductions for almost all patients. The 15 reported
cases where they did not do this, concerned patients with a lower
overall cardiovascular risk (mean risk score 4.2 v 7.2). In more
than two thirds of the consultations the providers reported that
they had involved the patient in the treatment decisions (table
4). Additional consultations were planned in 16 of the 185 cases
(9%). For 75 consultations, the healthcare provider made a
specific remark about the use of the decision aid (table 5⇓).
Most were positive remarks related to patient experiences
(n=32), who perceived the information as useful, clear,
reassuring, or motivating. There were 10 reports of patients who
had been encouraged by the aid to improve their lifestyle, and
four who had been motivated to disclose that they had stopped
taking a drug or were willing to start again. The providers
reported that 13 patients had been concerned or reluctant, and
seven had been irritated by the information. The healthcare
providers perceived the information as not needed for eight
patients and not motivating for lifestyle problems for another
eight patients. For five patients, there were some practical
concerns. Finally, six patients reported difficulties in completing
the pre-intervention questionnaires.
Discussion
Our study does not provide evidence that a patient oriented
treatment decision aid dealing with multiple clinical domains
for people with diabetes improves patient empowerment for
setting and achieving goals by a important amount. Only 46%
of the intervention patients reported that they had received the
basic elements of the intervention. No consistent changes were
observed in other patient reported outcomes, such as satisfaction
with care, beliefs about drugs, negative emotions, or general
health status. In general, no significant changes were seen for
drug treatment. The printed version of the intervention may
have increased lipid regulating treatment in poorly controlled
patients. Most patients did not perceive the information as
difficult. For some patients, the healthcare providers perceived
the information as not needed or not motivating.
Strengths and weaknesses of this study
We developed a decision aid using a theoretical framework,
following the International Patient Decision Aids Standards,
and tested its effectiveness in a randomised trial conducted in
a routine practice setting.33 34 The aid was developed to fit in
with the workflow in Dutch primary care and deal with many
of the drawbacks of previously developed decision aids.22 It can
be characterised as a minimal intensity strategy that requires
little extra time to conduct. We provided a short training session
in risk communication with the aid for healthcare providers but
no formal assessment was done on whether they were able to
engage patients in a dialogue. To be included, however, they
needed to have followed a course in motivational interviewing
to ensure a comparable level of training in communication skills
in all practices.
The most obvious weakness was the limited use of the decision
aid. In our study, the aid was used before and during only one
regular diabetes check-up. One might question whether single
exposure to an intervention can substantially change patient
empowerment. For chronic diseases, a decision aid should
ideally be used when needed and repeatedly over time. Exposure
seems to be a relevant factor when involving patients in tailored
interventions,35 and more effect of the aid could be anticipated
when it is used more often in the course of disease management.
Also, the healthcare providers were not accustomed to using
the decision aid, and their level of motivation and expertise may
improve with routine use of the aid in daily practice. We did
not assess what actually happened during the consultations but
evaluated the use of the aid in post-intervention questionnaires.
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The healthcare providers sometimes perceived the information
as unneeded. It seemed that the decision aid was not used as
intended in a substantial number of the patients, who were on
average somewhat older and had fewer uncontrolled risk factors.
We expected that increased patient empowerment would
translate as more patient involvement in setting and achieving
treatment goals. This could lead to more but also less intensified
treatment, depending on the patient’s goals. Given the existing
levels of suboptimal treatment, however, we expected that in
general the decision aid would lead to intensified drug treatment.
We included four measures assessing changes in drug treatment.
Observing a change in only one of them for the printed version
of the aid could be a chance finding. In the post-intervention
interviews, however, it was explicitly mentioned that some
patients had been motivated by the intervention to start using a
drug.
Patients participating in this study were on average about five
years younger but had a similar duration of diabetes to the
population of people with type 2 diabetes managed in Dutch
primary care.4 5Nevertheless, the age distribution was wide and
the effect of the intervention seemed not to be affected by age.
Although most patients included in our study showed some
potential for improved management of their risk factors, the
risk factors were on average relatively well controlled.
Participating practices may be more open to shared decision
making and already have a high level of chronic disease
management.
We chose a pragmatic design, evaluating the effect of the
intervention between patient groups since this was a first test
of a novel type of decision aid. If the aid is found to be
beneficial, it can be tested on a larger scale, also taking practice
level factors into account. Our design with patients randomised
within practices increases the risk of contamination in the control
group, and thus decreases the power to detect the effects of the
intervention. Both patients and providers may be affected,
resulting in improvements in the usual care group from study
participation. This design, however, was deemed necessary to
ensure that variations in communication skills and practice
organisation were balanced between the intervention and usual
care groups. In addition, when practices are randomised to a
non-intervention arm it may induce low participation and high
drop-out rates. To prevent direct contamination, the decision
aid could not be used for patients other than the intervention
patients. None the less, it was possible that healthcare providers
used some of the aspects learnt from working with the novel
approach in their usual care. We observed some differences in
clinical and patient reported outcomes between intervention and
control patients, indicating that our randomisation did not fully
work. Therefore, we conducted additional analysis incorporating
adjustment on unbalanced baseline characteristics, but this did
not change our main conclusions.
Strengths andweaknesses in relation to other
studies
So far, only a few computer based or web based disease
management systems have been tested that offer tailored status
reports with reminders or recommendations for individual
patients.36 37 This is an area that is rapidly evolving owing to the
increased attention for patient empowerment as well as
improving patient-provider communication and shared decision
making. Implementing such supportive systems has become
more feasible in various settings owing to the increasing use of
electronic medical records and internet access. Effective
communication involves patients receiving tailored information
and being encouraged to express concerns about the
recommended treatment.38 Recently, one study described the
development of a web based tool designed to facilitate the
articulation of patients’ often unvoiced agendas, which patients
have to complete before a consultation with their diabetologist.39
Our study is one of the first to evaluate the impact of such an
intervention.
In people with poorly controlled diabetes, computer or web
based aids have shown potential to improve HbA1c levels.36 37
Although a decision aid could also motivate well controlled
patients to maintain optimal control, these patients are often
excluded from these studies. Furthermore, most decision aids
that have been developed and tested for people with diabetes
focus on healthy behaviour and self monitoring skills and not
on drug treatment.40 41Recently, some aids have been developed
that also present drug treatment as a possible option to patients
but their effects have not yet been evaluated.20 21 One exception
is the paper based “diabetes medication choice” aid, which can
be used during consultation to encourage patients to voice their
opinions about drug options to the clinician.42This aid was found
to be effective for involving those patients who were eligible
for a treatment change in the decision-making process.33 43
Although the healthcare providers stated that they provided and
discussed the information in the majority of the consultations,
more than half of the patients reported not having received it as
planned. It is possible that in some of these cases the providers
only discussed the information briefly. Previously, it was found
that healthcare providers underestimate the level of involvement
that patients want, and providers have difficulties estimating
the information needs of people with diabetes.44 45 This may
contribute to an overly optimistic view of a shared decision
-making process.
Few studies have looked at possible negative effects of decision
aids for people with diabetes. We included several secondary
patient outcomes to provide insight into how aid may affect
diabetes care and patient outcomes beyond its primary aim.We
observed no apparent negative effects of our decision aid. There
were no changes in satisfaction with care or general health
outcomes. This finding is consistent with the conclusion of a
recent Cochrane review about the effects of decision aids for
people facing health treatment or screening decisions.19 In
addition, we did not see any adverse effects in diabetes related
negative emotions.
Meaning of the study
Our study showed that a patient oriented treatment decision aid
dealing with multiple clinical domains for people with diabetes
did not significantly increase patient empowerment for setting
and achieving goals in Dutch primary care. The printed version
of our intervention showed some effect on lipid regulating
treatment for patients with poorly controlled low density
lipoprotein cholesterol. Given our multiple testing, this could
be a chance finding. We can only speculate why no changes
were seen for blood pressure and glucose regulating treatment.
Possibly, the fact that most patients were already prescribed one
or more drugs for these risk factors limited the options or
willingness for additional drug treatment. In our setting, mostly
nurse practitioners and specialised assistants conducted the
consultations using the aid. We do not know whether this
affected its impact.
Our finding that the decision aid was not used to its full extent
in a substantial number of patients is a matter of concern. These
patients could not remember receiving or discussing the decision
aid. They were more often patients who were well controlled
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or had a low risk for cardiovascular complications. Given the
comments of several healthcare providers that they sometimes
perceived the information as unneeded, the aid may be more
effective when it is used more selectively. A flexible method,
where the aid can be offered to all patients before the
consultation but used selectively during consultation, might be
a sensible approach for routine care. The printed version seemed
to show more effect than the computer screen version. Several
patients expressed a preference for the printed version.
Healthcare providers mentioned that patients more often needed
assistance when using the computer screen version. Considering
the average age and educational level of the current population
with diabetes, printing the tailored information seems to be the
preferable choice at present.
Future research
Several problems have not yet been tackled. Firstly, the
intervention may have motivated patients to improve their drug
taking behaviour, which was not assessed in our study. A
follow-up study will be conducted to assess the impact of the
intervention on several clinical outcomes. When patients
improve their drug taking behaviour, this can be reflected in
better clinical outcomes. Secondly, qualitative interviews with
the healthcare providers were conducted after completion of the
intervention study to collect their experiences with the decision
aid in more depth. A future study examining these additional
data may help to identify relevant elements and barriers for
effective use of the aid. Finally, future studies are needed to
evaluate effects of repeated and more tailored use of the aid
applied in routine care, and studies could be conducted using
similar decision aids in other patient populations and settings.
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decision making
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domains for which treatment is indicated
The effect of the newest generation decision aids that prioritise between domains to guide treatment decisions have not yet been
evaluated in a randomised controlled study
What this study adds
The use of a patient oriented treatment decision aid tackling multiple clinical domains for people with diabetes did not improve patient
empowerment by an important amount
The printed version of the decision aid showed limited effects on treatment decisions about lipid regulation
Future studies are needed to evaluate the effects of repeated and flexible use of the decision aid in routine care
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Tables
Table 1| Baseline characteristics of participants. Values are numbers (percentages) unless stated otherwise
Standardised differenceUsual care (n=119)Intervention (n=225)Characteristics
0.02961.5 (8.5)61.8 (8.5)Mean (SD) age (years)
0.07354 (46)94 (42)Females
0.01745 (38)90 (40)Low educational attainment*
Diabetes duration:
6 (4)6 (3)Median (interquartile range)




0.16934 (29)81 (37)Sulphonylurea derivatives
0.1755 (5)19 (9)Other glucose regulating drugs
0.03349 (42)89 (40)Diuretics
0.02540 (34)72 (33)β blockers
0.06124 (21)40 (18)Calcium antagonists
0.10744 (37)95 (43)Angiotensin converting enzyme inhibitors
0.03625 (21)44 (20)Angiotensin II receptor blockers
0.09887 (74)174 (78)Statins
0.0286 (5)10 (5)Other lipid regulating drugs
0.11367 (57)114 (51)Related drug use (>3 drugs)
0.02071 (60)132 (59)Polypharmacy (>4 drugs for chronic illnesses)
Risk factors
0.27754 (46)72 (32)Uncontrolled HbA1c (≥7%)
0.0886.8 (0.7)6.8 (0.7)Mean (SD) HbA1c
0.16449 (42)111 (50)Uncontrolled SBP (≥140 mm Hg)
0.129137.1 (15.2)139.1 (16.0)Mean (SD) SBP
0.09045 (38)95 (43)Uncontrolled LDL (≥2.5 mmol/L)
0.1212.4 (0.8)2.5 (0.9)Mean (SD) LDL
0.0411.4 (0.9)1.4 (0.9)Mean (SD) No of uncontrolled risk factors
0.15711 (10)25 (12)Microalbuminuria or macroalbuminuria
0.07820 (17)45 (20)Smoking
Patient reported outcomes (mean (SD))
Diabetes empowerment scale:
0.1543.7 (0.4)3.6 (0.5)Setting goals
0.0493.5 (0.4)3.5 (0.4)Readiness to change
0.1343.8 (0.4)3.7 (0.5)Psychosocial management






0.03711.5 (12.9)12.0 (13.6)Problem area in diabetes
0.3040.91 (0.10)0.86 (0.18)EQ5D-NL
SBP=systolic blood pressure; LDL=low density lipoprotein cholesterol; PEQD=patients’ evaluation of quality of diabetes care; EQ5D-NL=Dutch Euro quality of life.
*Not more than primary school or lower vocational education.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g5651 doi: 10.1136/bmj.g5651 (Published 25 September 2014) Page 9 of 14
RESEARCH
Table 2| Patient reported outcomes at follow-up, and intervention effects (linear regression models)
Baseline adjusted effectUsual careIntervention
Outcomes P valueEffect size (95% CI)Mean (SD)NoMean (SD)No
Primary outcome
0.4240.039 (−0.056 to 0.134)3.7 (0.4)1083.7 (0.5)207DES setting and achieving goals
Secondary outcomes
Diabetes empowerment scale:
0.710−0.017 (−0.104 to 0.071)3.6 (0.5)1083.6 (0.5)207Readiness to change
0.917−0.005 (−0.094 to 0.085)3.8 (0.5)1083.8 (0.5)204Psychosocial management
Beliefs about medication questionnaire:
0.241−0.314 (−0.839 to 0.210)18.8 (3.3)10718.8 (3.1)205Necessity
0.1830.442 (−0.207 to 1.092)14.0 (3.7)10714.2 (3.4)205Concerns
0.1240.385 (−0.104 to 0.874)10.5 (2.6)10810.9 (2.5)206Overuse
0.4130.186 (−0.259 to 0.630)11.9 (2.6)10811.8 (2.5)204Harm
0.679−0.728 (−4.177 to 2.721)62.8 (20.6)10862.0 (19.5)205PEQD
0.0512.115 (−0.004 to 4.234)9.9 (11.1)10712.2 (14.5)204Problem areas in diabetes
0.692−0.006 (−0.035 to 0.023)0.91 (0.13)1050.88 (0.17)203EQ5D-NL
PEQD=Patients’ evaluation of quality of diabetes care; EQ5D-NL=Dutch Euro quality of life.
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Table 3| Drug treatment and smoking status at follow-up, and intervention effects (logistic regression models)
P valueOdds ratio (95% CI)
Usual careIntervention
Criteria in eligible patients No (%)No eligibleNo (%)No eligible
Intensified treatments by baseline measures:
0.9521.03 (0.44 to 2.41)12 (24)5116 (24)68Glucose: HbA1c ≥7%
0.8820.93 (0.37 to 2.34)8 (17)4817 (16)107Blood pressure: SBP ≥140 mm Hg
0.0812.54 (0.89 to 7.23)5 (12)4422 (25)88Lipids: LDL ≥2.5 mmol/L
0.6461.27* (0.46 to 3.53)69 (60)115133 (63)214Prescribed RAS inhibiting treatment
0.4250.40* (0.04 to 3.77)17 (18)9832 (18)184Documented smoking status (yes)
SBP=systolic blood pressure; LDL=low density lipoprotein cholesterol; RAS=renin angiotensin system.
*Baseline adjusted model.
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Table 4| Process evaluation per intervention format: patient characteristics and reported use of decision aid by patient and healthcare




61.3 (9.6)64.2 (7.0)61.1 (6.7)60.4 (10.0)Mean (SD) age
28 (48)27 (48)17 (31)22 (42)Female
3 (5)3 (5)13 (24)8 (15)Diabetes duration <3 years
6.1 (4.1)8.0 (9.4)7.4 (4.2)6.3 (4.6)Mean (SD) UKPDS risk score
1.2 (0.9)1.3 (0.9)1.6 (0.9)1.4 (0.9)Mean (SD) number of uncontrolled risk factors
29 (50)38 (67)35 (63)30 (57)Polypharmacy (>4 drugs for chronic illness)
56 (95)55 (97)53 (95)53 (100)Intervention consultation planned
50484952Patient reports
41 (82)38 (79)41 (84)40 (77)Received information before consultation





711——Printed better than screen version
2319——Printed similar to screen version
10——Screen better than printed version
34 (68)36 (75)41 (84)39 (75)Discussion of risks
27 (54)33 (69)34 (69)40 (77)Discussion on possible risk reduction
22 (44)25 (52)25 (51)31 (60)Reported intervention as per protocol
21 (42)20 (42)16 (33)13 (25)Use of treatment cards
53533643Provider reports
53 (100)53 (100)36 (100)41 (95)Patient read information before consultation
7701Patient assisted by practice staff
48 (91)52 (98)30 (83)37 (86)Provider discussed possible risk reduction
Provider involved patient in decisions:
33 (62)37 (70)29 (81)29 (67)Yes
9/812/20/75/3Not applicable*/missing
3205No
8 (15)7 (13)2 (6)0 (0)Provider used treatment cards
2653Additional consultation planned
UKPDS=United Kingdom Prospective Diabetes Study.
*Risk factors controlled therefore patients’ involvement in treatment decisions was unnecessary.
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Table 5| Remarks by healthcare providers about decision aid related to individual patient consultations
No of casesClassification and description of remark
Patient positive:
17Motivating and/or involved in choice
10Confirming and/or reassuring
5Useful and/or clear information
32Total
Patient concerned or reluctant:
5Confronting and/or worrying information
2Difficult information
2Treatment option not possible
4Accepted risks as they were
13Total
Patient negative:
7Information not accepted or seen as nonsense
Provider reluctant:
8No additional value, no action possible
2Other priorities for patient, no time for aid
10Total
Provider negative:
8Not motivating for reducing BMI or stop smoking
Practical issues:
3Input from medical record not complete / updated
2Dutch language, reading glasses needed
5Total
BMI=body mass index.
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Figure
Flow of patients through study
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